Tiotropium for treatment of stable COPD: A meta-analysis of clinically relevant outcomes

Abebaw Mengistu Yohannes; Thomas George Willgoss; Jørgen Vestbo

doi:10.4187/respcare.00852

Tiotropium for treatment of stable COPD: A meta-analysis of clinically relevant outcomes

Abebaw Mengistu Yohannes, Thomas George Willgoss, Jørgen Vestbo

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: To systematically review recent evidence on the effectiveness of tiotropium versus placebo, ipratropium, and long-acting β2 agonists on outcomes relevant to patients with stable COPD, including health-related quality of life, dyspnea, exacerbations and hospitalizations. METHODS: Our inclusion criteria for trials were: ≥ 12 weeks; compared tiotropium to placebo, ipratropium, or long-acting /3 agonists; patients ≥ 40 y old and with stable COPD. Sixteen trials (16,301 patients) met the inclusion criteria. RESULTS: Tiotropium improved health-related quality of life (measured with St George's Respiratory Questionnaire) compared to placebo (odds ratio [OR] 1.61, 95% CI 1.38-1.88, P

Original language	English
Pages (from-to)	477-487
Number of pages	10
Journal	Respiratory Care
Volume	56
Issue number	4
DOIs	https://doi.org/10.4187/respcare.00852
Publication status	Published - Apr 2011

Keywords

COPD
Dyspnea
Exacerbations
Hospitalization
Meta-analysis
Quality of life
Tiotropium

Access to Document

10.4187/respcare.00852

http://www.ingentaconnect.com/search/download?pub=infobike%3a%2f%2fjrcc%2frc%2f2011%2f00000056%2f00000004%2fart00011&mimetype=application%2fpdf&exitTargetId=1303827361510

Cite this

@article{fa7d736bfd954ce088280188b8f98726,

title = "Tiotropium for treatment of stable COPD: A meta-analysis of clinically relevant outcomes",

abstract = "OBJECTIVE: To systematically review recent evidence on the effectiveness of tiotropium versus placebo, ipratropium, and long-acting β2 agonists on outcomes relevant to patients with stable COPD, including health-related quality of life, dyspnea, exacerbations and hospitalizations. METHODS: Our inclusion criteria for trials were: ≥ 12 weeks; compared tiotropium to placebo, ipratropium, or long-acting /3 agonists; patients ≥ 40 y old and with stable COPD. Sixteen trials (16,301 patients) met the inclusion criteria. RESULTS: Tiotropium improved health-related quality of life (measured with St George's Respiratory Questionnaire) compared to placebo (odds ratio [OR] 1.61, 95% CI 1.38-1.88, P",

keywords = "COPD, Dyspnea, Exacerbations, Hospitalization, Meta-analysis, Quality of life, Tiotropium",

author = "Yohannes, {Abebaw Mengistu} and Willgoss, {Thomas George} and J{\o}rgen Vestbo",

year = "2011",

month = apr,

doi = "10.4187/respcare.00852",

language = "English",

volume = "56",

pages = "477--487",

journal = "Respiratory Care",

issn = "0020-1324",

publisher = "Daedalus Enterprises Inc",

number = "4",

}

TY - JOUR

T1 - Tiotropium for treatment of stable COPD: A meta-analysis of clinically relevant outcomes

AU - Yohannes, Abebaw Mengistu

AU - Willgoss, Thomas George

AU - Vestbo, Jørgen

PY - 2011/4

Y1 - 2011/4

N2 - OBJECTIVE: To systematically review recent evidence on the effectiveness of tiotropium versus placebo, ipratropium, and long-acting β2 agonists on outcomes relevant to patients with stable COPD, including health-related quality of life, dyspnea, exacerbations and hospitalizations. METHODS: Our inclusion criteria for trials were: ≥ 12 weeks; compared tiotropium to placebo, ipratropium, or long-acting /3 agonists; patients ≥ 40 y old and with stable COPD. Sixteen trials (16,301 patients) met the inclusion criteria. RESULTS: Tiotropium improved health-related quality of life (measured with St George's Respiratory Questionnaire) compared to placebo (odds ratio [OR] 1.61, 95% CI 1.38-1.88, P

AB - OBJECTIVE: To systematically review recent evidence on the effectiveness of tiotropium versus placebo, ipratropium, and long-acting β2 agonists on outcomes relevant to patients with stable COPD, including health-related quality of life, dyspnea, exacerbations and hospitalizations. METHODS: Our inclusion criteria for trials were: ≥ 12 weeks; compared tiotropium to placebo, ipratropium, or long-acting /3 agonists; patients ≥ 40 y old and with stable COPD. Sixteen trials (16,301 patients) met the inclusion criteria. RESULTS: Tiotropium improved health-related quality of life (measured with St George's Respiratory Questionnaire) compared to placebo (odds ratio [OR] 1.61, 95% CI 1.38-1.88, P

KW - COPD

KW - Dyspnea

KW - Exacerbations

KW - Hospitalization

KW - Meta-analysis

KW - Quality of life

KW - Tiotropium

U2 - 10.4187/respcare.00852

DO - 10.4187/respcare.00852

M3 - Article

C2 - 21255503

SN - 0020-1324

VL - 56

SP - 477

EP - 487

JO - Respiratory Care

JF - Respiratory Care

IS - 4

ER -

Tiotropium for treatment of stable COPD: A meta-analysis of clinically relevant outcomes

Abstract

Keywords

Access to Document

Fingerprint

Cite this